Yesterday, Moderna announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has concluded that a booster dose of the company’s coronavirus vaccine may be considered in people aged 18 years and older. MRNA stock has skyrocketed by more than 200% just this year. Its mRNA medicines work by directing the body’s cells to produce intracellular membrane or secreted proteins that have a therapeutic or preventive benefit to address a range of diseases. In detail, the company focuses on creating transformative medicine based on messenger RNA (mRNA). 3 Top Vaccine Stocks To Watch This Week As Pfizer-BioNTech Expand Their Vaccine Use Cases ModernaĪnother top company in the biotech space right now would be Moderna. Considering all these, would you be adding PFE stock to your portfolio? Source: TD Ameritrade TOS Overall, Pfizer believes it will continue to play a big role in eradicating the pandemic. This is in response to a series of unfortunate events that include the failure of some vaccine companies to scale up production of their vaccines, and the surge of the Delta variant. This result further emphasizes the need for a booster dose to ensure optimum protection against the disease.Īlso, the company recently announced that it will be ramping up the production of its COVID-19 vaccine next year. It appears that a booster administered to individuals previously receiving the company’s primary two-dose series restored vaccine protection against the virus to the high levels achieved after the second dose. The trial was conducted on more than 10,000 individuals 16 years of age and older. Last week, the company announced topline results from a Phase 3 randomized controlled trial evaluating the efficacy and safety of a 30-µg booster dose of the Pfizer-BioNTech COVID-19 vaccine. As some of you may be aware, the company partnered with BioNTech SE ( NASDAQ: BNTX) to develop one of the most effective coronavirus vaccines present today. Its global portfolio mainly consists of medicines and vaccines. Essentially, it is a research-based company that specializes in biopharmaceutical products. Dynavax Technologies Corporation ( NASDAQ: DVAX)įirst, we will be looking at the biopharmaceutical company, Pfizer.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |